A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis

Trial Profile

A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2015

At a glance

  • Drugs LY 3113593 (Primary) ; LY 3113593 (Primary)
  • Indications Renal failure
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 04 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 Dec 2014 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
    • 04 Dec 2014 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top